SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Ariad Pharmaceuticals Inc. and Advises Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Ariad Pharmaceuticals Inc. ("Ariad" or the "Company") ARIA concerning possible violations of federal securities laws.

If you purchased or otherwise acquired Ariad shares and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm's website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The investigation focuses on whether Ariad and certain of its officers and/or directors violated federal securities laws. On October 6, 2016, a report called, "How Ariad Pharma Used a Safety Problem to Jack Up a Cancer Drug's Price," explained the ways Ariad inflated the price for its leukemia drug Iclusig. On October 14, 2016, Senator Bernie Sanders criticized Ariad for hiking its drug prices.

If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161028005788/en/